Sage climbs as Huntington's drug found to be safe in mid-stage study

Sage Therapeutics

11/06/2024 12:31

** Shares of Sage Therapeutics  SAGE.O  rise 1.8% to $11.10
premarket
    ** Drug developer says its drug, dalzanemdor, was found to
be safe in patients with a rare, genetic neurological condition
called Huntington's disease in a part of a mid-stage study
    ** SAGE says the study in Huntington's disease patients was
not designed to show a statistically significant difference
between the drug dalzanemdor and placebo
    ** Up to last close, stock down 49.7% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))